Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

  • Technology appraisal guidance
  • TA1126
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence